| .证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-060 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于控股股东部分股份解除质押及质押、展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）于近日接到控股股东 淄博蓝帆投资有限公司（以下简称"蓝帆投资"）的通知，获悉蓝帆投资将其持有的本 公司部分股份办理了解除质押及质押、展期手续，具体情况如下： 上述股份的原质押情况，详见公司分别于 2021 年 10 月 8 日、2022 年 2 月 9 日、 2022 年 4 月 21 日、2022 年 4 月 23 日、2022 年 4 月 27 日、2022 年 5 月 18 日、2022 年 9 月 29 日披露在指定信息媒体的《关于公司控股股东进行股票质押式回购交易的公 告》（公告编号：2021-088）、《关于公司控股股东部分股份质押的公告》（公告编号：2022- 009）、《关于公司控股股东部分 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-056 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 17.84 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 5、截至 2023 年 9 月 21 日，蓝帆医疗股份有限公司（以下简称"公司"）股票已 有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发"蓝帆转债"转股价格向 下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股 价格，并及时履行信息披露义务。 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 2 ...

蓝帆医疗股份有限公司 2023 年半年度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市临淄区稷下街道一诺路 48 号） 二〇二三年半年度报告 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 刘胜军先生 | 独立董事 | 公务原因 | 董书魁先生 | 本半年度报告第三节"管理层讨论与分析"中涉及部分前瞻性陈述，均不构 成公司对投资者及相关人士的实质承诺，投资者及相关人士均应对此保持足够 的风险认识；同时本章节分析了公司经营过程中可能存在的风险及应对措施， 敬请投资者关注相关内容并注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 股票代码：002382 二〇二三年八月 1 蓝帆医疗股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人刘文静、主管会计工作 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-051 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解除 质押股份 数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 起始日 解除 日期 质权人 蓝帆 投资 是 23,000,000 9.80 2.28 2020 年 8 月 31 日 2023 年 8 月 9 日 兴业银行 股份有限 公司淄博 6,000,000 2.56 0.60 分行 2021 年 6 月 24 日 2023 年 8 月 9 日 合计 29,000,000 12.35 2.88 - - - 一、股东股份解除质押的基本情况 | 股 东 | 是否为 控股股 东或第 | 本次质押 | 占其 所持 | 占公 司总 | 是否 | 是否 为补 | 质押起 | | 质押 ...

证券代码：002382 证券简称：蓝帆医疗 编号：202307 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 广发证券、鑫元基金、上银基金、泰康资产、长江养老、浙商资管、 参与单位名称及 东方财富、山西证券等机构的 8 名投资者 人员姓名 时间 2023 年 6 月 9 日 9:30-12:30 地点 蓝帆医疗山东总部 副总裁、董事会秘书、首席法务官 黄婕女士 上市公司接待人 防护事业部海外营销中心总经理 李斌先生 员姓名 一、黄婕女士介绍公司概况 （一）2022 年度公司整体业绩概况 2022 年度公司实现营业收入 49 亿元、归母净利润-3.7 亿元。 公司持续深耕研发，2022 年研发投入 3.99 亿元，研发费用 3.52 亿 元。同时，对同心医疗的核算重分类到其他非流动金融资产确认投 资收益 2.7 亿元，考虑税后贡献利润约 2.3 亿元。2022 年实现经营 活动产生的现金流量净额为 4.94 亿元，给公司的成长和发展注入了 投资者关系活动 必要的血液。 主要内容介绍 （二）2023 年 Q1 公司整体业绩概况 2023 ...

证券代码：002382 证券简称：蓝帆医疗 | --- | --- | --- | |----------------|--------------------|--------------| | | | 编号：202306 | | | □特定对象调研 | | | | □媒体采访 ■ | | | 投资者关系活动 | | | | | □新闻发布会 | | | 类别 | | | | | □现场参观 | | | | □其他（电话会议） | | | 参与单位名称及 | 参与公司 2022 | | | 人员姓名 | | | | 时间 | 2023 年 5 月 24 | | | | "看财经"平台 | | | 地点 | （ | | | | | | | | 董事长 | 刘文静女士 | | | 董事、总裁 | 钟舒乔先生 | | 上市公司接待人 | 董事 | 于苏华先生 | | 员姓名 | 独立董事 | 刘胜军先生 | | | 副总裁、首席财务官 | 崔运涛先生 | | | | 黄婕女士 | 一、黄婕女士致辞 首先，非常荣幸大家能于百忙之中参加蓝帆医疗 2022 年度业 绩说明会。我代表蓝帆医疗，向今天参加说明会的各位投资者 ...

证券代码：002382 证券简称：蓝帆医疗 | --- | --- | |----------------|-------------------------| | | ■特定对象调研 | | | □媒体采访 □ | | 投资者关系活动 | | | | □新闻发布会 | | 类别 | | | | □现场参观 | | | ■其他（电话会议） | | | | | | | | | UBS、Abrdn、 | | | Eastspring、EPF、 | | 参与单位名称及 | | | 人员姓名 | Asset Management | | | Public Mutual、 | | | Urusharta Jamaah (UJSB) | | | Hong Kong、PNB | 时间 2023 年 5 月 16 日-2023 年 5 月 18 日 地点 蓝帆医疗山东总部+电话会议 董事长 刘文静女士 上市公司接待人 副总裁、董事会秘书、首席法务官 黄婕女士 员姓名 防护事业部海外营销中心总经理 李斌先生 一、刘文静女士、黄婕女士分别介绍公司发展战略和业绩情况 （一）公司发展战略 公司于 2003 年成立，成立之初以生产、销 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-029 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 蓝帆医疗股份有限公司（以下简称"公司"）《2022 年年度报告》及摘要已于 2023 年 4 月 29 日披露在巨潮资讯网（http://www.cninfo.com.cn），为便于广大投资者更全面 深入地了解公司经营情况，公司将于 2023 年 5 月 24 日（星期三）下午 15：00-17：00 举行 2022 年度网上业绩说明会。现将具体情况公告如下： 本次业绩说明会通过"看财经"平台以网络远程的方式举行，投资者可登录"看 财经"平台参与本次业绩说明会（https://apphope6rv09034.h5.xiaoeknow.com/v2/course/ alive/l_64648af7e4b0f2aa7deb9de2）。 三、业绩说明会出席人员 公司董事长 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,094,194,474.12, a decrease of 15.70% compared to ¥1,297,931,282.98 in the same period last year[6] - The net loss attributable to shareholders for Q1 2023 was ¥77,299,820.11, worsening by 47.38% from a loss of ¥52,449,217.46 in the previous year[6] - Total operating revenue for Q1 2023 was ¥1,094,194,474.12, a decrease of 15.7% compared to ¥1,297,931,282.98 in Q1 2022[31] - Net profit for Q1 2023 was a loss of ¥77,299,820.11, compared to a loss of ¥52,449,233.12 in Q1 2022, representing a 47.3% increase in losses[32] - Other comprehensive income for Q1 2023 was a loss of ¥61,212,648.44, contrasting with a gain of ¥69,619,253.46 in Q1 2022[32] - The total comprehensive income for the first quarter was -138,512,468.55 CNY, compared to 17,170,020.34 CNY in the previous period[33] Cash Flow - The net cash flow from operating activities was negative at ¥31,920,809.05, a decline of 139.96% compared to a positive cash flow of ¥79,891,133.16 in the same period last year[6] - Net cash flow from operating activities decreased by CNY 111,811,942.21, a decline of 139.96% compared to the same period last year[22] - Cash inflow from operating activities totaled 1,243,607,312.84 CNY, down from 1,526,335,137.12 CNY year-over-year[35] - Cash outflow from operating activities was 1,275,528,121.89 CNY, compared to 1,446,444,003.96 CNY in the previous year[35] - The net cash flow from investing activities was -280,068,693.09 CNY, a significant decrease from 610,933,764.71 CNY in the previous period[35] - Cash and cash equivalents decreased by CNY 842,446,946.27, a decline of 223.73% compared to the same period last year[22] - Cash and cash equivalents at the end of the period were 1,409,936,548.73 CNY, down from 2,297,012,302.47 CNY at the end of the previous year[35] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥15,488,809,918.91, a decrease of 2.42% from ¥15,872,538,527.91 at the end of the previous year[6] - Current liabilities due within one year increased by CNY 729,181,014.27, reflecting a growth of 338.76% compared to the previous period[17] - Current liabilities increased to ¥2,880,980,391.82, up 26.4% from ¥2,278,678,622.53 in the previous year[31] - Long-term borrowings decreased significantly to ¥544,499,093.66 from ¥1,386,209,391.27, a reduction of 60.7%[31] - The total equity attributable to shareholders decreased to ¥10,419,346,142.23 from ¥10,551,930,175.12, a decline of 1.3%[31] Business Segments - The heart and brain division achieved sales revenue of ¥265 million in Q1 2023, an increase of over 40% from ¥188 million in the same period last year[10] - The company’s first drug-coated balloon product, BA9™ DCB, began to generate sales, contributing positively to revenue growth[11] - The company’s glove business is experiencing a recovery, with nitrile glove orders increasing significantly since March 2023, indicating a positive market trend[13] - The nursing division reported a profit exceeding ¥6.8 million in Q1 2023, representing an increase of over 28% year-on-year[14] Investments and Shareholder Information - The company recognized a fair value gain of ¥70,309,200 from its investment in a medical device company during the reporting period[14] - The total number of common shareholders at the end of the reporting period is 104,201[25] - The largest shareholder, Zibo Lanfan Investment Co., Ltd., holds 23.20% of shares, totaling 233,621,909 shares, with 160,780,000 shares pledged[25] - The second-largest shareholder, Beijing Xinyu Investment Center, holds 2.51% of shares, totaling 25,297,561 shares[25] - The top ten shareholders collectively hold a significant portion of the company's shares, with the first three shareholders accounting for over 27% of total shares[25] - The company has not disclosed any known relationships among other shareholders or any potential concerted actions as per regulations[25] Other Financial Metrics - The company’s weighted average return on equity was -0.74% for Q1 2023, compared to -0.50% in the same period last year[6] - Research and development expenses for Q1 2023 were ¥71,330,456.77, slightly down from ¥73,730,586.30 in Q1 2022[32] - The company reported an investment income of ¥6,827,686.29, recovering from a loss of ¥17,494,475.71 in the previous year[32] - Financial expenses increased by CNY 45,355,924.19, a growth of 331.46% compared to the same period last year[19] - Other income rose by CNY 4,619,817.93, reflecting a growth of 40.06% compared to the same period last year[19] - Investment income increased by CNY 24,322,162, representing a growth of 139.03% compared to the same period last year[19] Future Plans and Certifications - The company has announced plans for a non-public issuance of A-shares, with relevant approvals obtained from the Shandong Provincial Development and Reform Commission[27] - The company has received registration certification in Indonesia for its transcatheter aortic valve and balloon dilation catheter products[27] - The company is involved in the issuance of convertible bonds, with updates provided on the conversion conditions and stock price adjustments[27]

Financial Performance - The company's operating revenue for 2022 was ¥4,900,477,569.52, a decrease of 39.56% compared to ¥8,108,586,464.73 in 2021[18]. - The net profit attributable to shareholders was -¥372,316,293.48, representing a decline of 132.22% from ¥1,155,709,191.19 in the previous year[18]. - The cash flow from operating activities was ¥494,468,136.59, down 77.98% from ¥2,245,545,736.13 in 2021[18]. - The basic earnings per share were -¥0.37, a decrease of 132.74% compared to ¥1.13 in 2021[18]. - Total assets at the end of 2022 were ¥15,872,538,527.91, a reduction of 6.16% from ¥16,913,875,507.52 at the end of 2021[18]. - The weighted average return on equity was -3.53%, down from 10.32% in 2021[18]. - The company reported a net loss of -¥657,173,477.89 after deducting non-recurring gains and losses, a significant decline from a profit of ¥62,125,153.70 in 2021[18]. - In Q4 2022, the net profit attributable to shareholders was -¥227,605,234.64, following a profit of ¥35,721,598.27 in Q3 2022[22]. - The company recognized government subsidies amounting to ¥66,122,197.62 in 2022, compared to ¥49,664,503.87 in 2021[24]. Business Strategy and Market Position - The company reported a change in its main business from health protection to include medical devices and nursing services[17]. - The company’s strategic upgrade in 2021 redefined its approach to "new healthcare + big health," entering the new retail market to enhance its domestic marketing strategy[29]. - The company is positioned as a multinational comprehensive platform in the medical device industry, focusing on technological innovation for high-quality development[29]. - The company has established a multi-business layout combining high-value, medium-value, and low-value consumable products, focusing on cardiovascular devices, health protection gloves, and emergency care supplies[38]. - The company is actively expanding into the export market for emergency kits for new energy vehicles, collaborating with more automotive manufacturers[46]. - The company aims to enhance its brand influence and product innovation, focusing on global expansion and high-quality development in 2023[152]. Product Development and Innovation - The company has launched new products, including nitrile anesthesia gloves and new color options, with domestic sales of disposable latex gloves increasing by over 240% year-on-year[35]. - The company has developed a fully automated production line, optimizing efficiency and ensuring high-quality medical gloves[43]. - The company is committed to continuous innovation and R&D to provide comprehensive emergency rescue solutions for various market scenarios[47]. - The company has launched multiple products in the surgical field, achieving sales and recognition in various provinces in China[83]. - The company is focusing on high-value consumables in the cardiovascular sector, leveraging a global R&D clinical platform and clinical data from top hospitals[164]. Market Trends and Growth Opportunities - The company’s cardiovascular business is projected to grow significantly, with the global medical device market expected to reach approximately ¥4.447 trillion by 2025, and a compound annual growth rate (CAGR) of 7.10% from 2020 to 2025[29]. - In 2022, the high-value medical consumables market in China was approximately ¥177.9 billion, with a CAGR of about 20% over the past six years[31]. - The global first-aid kit market was valued at approximately ¥3.7 billion in 2022, with an expected growth to ¥6.1 billion by 2029, reflecting a CAGR of 7.3% from 2023 to 2029[35]. - The market size for drug-coated balloons in China is expected to reach ¥83.8 billion by 2024, with a compound annual growth rate of 17.7% from 2015 to 2019[145]. Operational Efficiency and Cost Management - The company is committed to improving production processes for its medical products, including heart stents and gloves, to enhance efficiency and quality[61][63][64]. - The company emphasizes cost management and efficiency improvements across all operational aspects to enhance overall competitiveness and gross margin[156]. - The nursing division is focusing on cost control through improved production efficiency and raw material management to reduce production costs[162]. Governance and Compliance - The company has implemented a governance structure that complies with regulatory requirements, enhancing operational transparency and accountability[173]. - The company actively engages with regulatory bodies to ensure compliance and improve information disclosure practices[180]. - The company held three shareholder meetings during the reporting period, ensuring compliance with relevant regulations and allowing all shareholders, especially minority shareholders, to exercise their rights fully[175]. Future Outlook and Projections - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[198]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on innovative healthcare solutions[198]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 500 million RMB allocated for this purpose[198].